Serum #2-microglobulin concentrations were determined in 21 untreated hyperthyroid patients (12 with Graves' disease, and nine with toxic nodular adenoma) and in 20 healthy controls. All subjects had normal serum creatinine concentrations and urine analysis. Both total and free thyroid hormones were significantly higher in the hyperthyroid groups than in controls. J2-microglobulin concentrations were significantly increased in both groups of hyperthyroid patients compared with controls. No difference was found in the thyroid hormone and f2-microglobulin concentrations between both sets of patients. The i2-microglobulin and thyroid hormone concentrations were not correlated. These data show that hyperthyroidism is another cause of increased f22-microglobulin production along with viral infections, immunologically mediated diseases, and malignant neoplasms. The increased serum #2-microglobulin concentration in thyroid hyperfunction is probably related to metabolic rate, even if autoimmunity might contribute to its overproduction.
were determined in 21 untreated hyperthyroid patients (12 with Graves' disease, and nine with toxic nodular adenoma) and in 20 healthy controls. All subjects had normal serum creatinine concentrations and urine analysis. Both total and free thyroid hormones were significantly higher in the hyperthyroid groups than in controls. J2-microglobulin concentrations were significantly increased in both groups of hyperthyroid patients compared with controls. No difference was found in the thyroid hormone and f2-microglobulin concentrations between both sets of patients. The i2- interactions." Activated T cells are increased in untreated patients; the suppressor-effector activity of CD8 + cells or suppressor-inducer function of CD4 + 2H4 + cells in thyroid glands are considerably impaired when compared with those in peripheral blood. These changed ratios may lead to increased activation of B lymphocytes.'2 13 Therefore, an increase in serum /2-microglobulin in Graves' disease might be a direct consequence of this lymphocytic derangement. Furthermore, the reduction of f2-microglobulin occurring during treatment with methimazole might be due to the effect of this drug on immune processes. 4 On the other hand, the high concentrations of /32-microglobulin reported in toxic nodular adenoma89 suggest that hyperthyroidism itself induces this through a metabolically mediated increase in fl2-microglobulin production. This hypothesis is further supported by the significant decrease of f2-microglobulin during antithyroid treatment, both in Graves' disease and toxic nodular adenoma. 8 Our data show that patients with untreated hyperthyroidism have significantly higher concentrations of serum f2-microglobulin than controls (Graves' disease v controls and toxic nodular adenoma v controls p < 0.01). As serum creatinine was normal in all subjects, the increased serum f#2-microglobulin in hyperthyroid patients is due to overproduction. There was no difference in thyroid hormones and /32-microglobulin concentrations between the group with Graves' disease and the group with toxic nodular adenoma, which also supports the hypothesis that the increased serum fl2-microglobulin concentrations represent mainly a hormonal effect rather than an expression of autoimmune dysfunction. As reported by Lervang and Mulder,89 we have not found any correlation between f2-microglobulin and thyroid hormone concentrations and therefore fl2-microglobulin can not be considered a reliable indicator of the degree of thyroid hyperfunction. The lack of correlation between serum #2-microglobulin and thyroid hormone concentrations might also suggest an additional role for immunological processes in the increase in f32-microglobulin production.
In summary, our findings show that hyperthyroidism must be borne in mind when interpreting increased serum f32-microglobulin 
